Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for July 7, 2020

7/6/2020

 
Regulatory Update
 
The FDA approved triheptanoin (Dojolvi, Ultragenyx) on 6/30/2020 as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). Ultragenyx set WAC for triheptanoin at $4,875 per 500 ml vial, which indicates an average annual cost of $138,000.
 
The FDA has approved remimazolam (Byfavo, Acacia) on 7/2/2020 for the induction and maintenance of procedural sedation in adults undergoing surgical procedures lasting 30 minutes or less.
 
The FDA approved fostemsavir (Rukobia, ViiV Healthcare), on 7/3/2020, in combination with other antiretrovirals, for the of treatment heavily treated adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
 
The FDA rejected Heron Therapeutics Bupivacaine, Meloxicam (HTX-011) for a second time and requested additional data regarding exposure of excipients in preclinical reproductive toxicology studies and a process change for the allowable level of an impurity during manufacturing.
 
Mezzion submitted an NDA for udenafil to improve the physiology of patients 12 years of age and older with single ventricle heart disease (SVHD) who have undergone a Fontan operation.
 
The FDA designated Nodic Nanovector Lutetium (177lu) lilotomab satetraxetan, a Fast Track therapy for treatment of adults with relapsed or refractory marginal zone lymphoma who received at least two prior systemic therapies.
 
Announced Research Updates
 
Iterum Therapeutics announced that in the 1,670 patient, Phase III SURE 1 trial, oral sulopenem/probenecid for five days did not meet non-inferiority for test of cure compared to oral ciprofloxacin for three days (66.8% vs 78.6%) in the treatment of uncomplicated urinary tract infections in patients infected with quinolone-susceptible bacteria. However, in patients infected with quinolone-resistant organisms, sulopenem/probenecid was superior to ciprofloxacin at the test of cure visit (62.6% vs 36%).
 
Hua announced that in a 24-week, 766 patient, Phase III trial, dorzagliatin added to metformin lowered HbA1c 0.66% compared to metformin monotherapy (a decrease of 1.02% vs 0.36%) in Chinese patients with type 2 diabetes.
 
Helsinn and MEI Pharma discontinued a Phase III trial evaluating pracinostat in combination with azacitidine in the treatment of acute myeloid leukemia patients who are unfit to receive standard intensive chemotherapy, when a futility analysis revealed little chance of treatment success.
 
ObsEva announced that in the 24-week, 526 patient, Phase III PRIMROSE 2 trial, heavy menstrual bleeding was reduced to 80/ml or less with the reduction being at least 50% from baseline in 75.5% of patients treated with linzagolix 200 mg and hormone add-back therapy and 56.4% with linzagolix 100 mg monotherapy compared to placebo in patients with uterine fibroids and heavy menstrual bleeding.
 
Published Research Updates
 
An analysis of post-marketing data from Japan found that 12.6% of 6,451 patients that took tofogliflozin experienced an ADR, with the most commonly reported events being hypoglycemia, polyuria/pollakiuria, volume depletion-related disorders, urinary tract infections, genital infections and skin diseases.
 
In a 52-week, 62 patient, Phase III trial, treatment with weekly somapacitan was similar to daily growth hormone in the reduction of visceral, subcutaneous and total adipose tissue in Japanese adults with growth hormone deficiency


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.